 <h1>FazaClo Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>clozapine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about clozapine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name FazaClo.</p><h2>In Summary</h2><p><b>Common side effects of FazaClo include:</b> hypotension, fever, tachycardia, constipation, dizziness, headache, nausea, sedated state, vomiting, and weight gain. <b>Other side effects include:</b> syncope, and diaphoresis.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to clozapine: oral suspension, oral tablet, oral tablet disintegrating</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Suspension; Tablet; Tablet, Disintegrating)</p><p>Severe Neutropenia; Orthostatic Hypotension; Bradycardia, and Syncope; Seizure; Myocarditis and Cardiomyopathy; Increased Mortality in Elderly Patients with Dementia-related PsychosisSevere Neutropenia: Clozapine can cause severe neutropenia, which can lead to serious and fatal infections. Patients initiating and continuing treatment with clozapine must have a baseline blood absolute neutrophil count (ANC) measured before treatment initiation and regular ANC monitoring during treatment.Clozapine is available only through a restricted program called the Clozapine Risk Evaluation Mitigation Strategy (REMS).Orthostatic Hypotension, Bradycardia, and Syncope: Risk is dose related. Starting dose is 12.5 mg. Titrate gradually and use divided dosages.Seizure: Risk is dose-related. Titrate gradually and use divided doses. Use with caution in patients with history of seizure or risk factors for seizure.Myocarditis, Cardiomyopathy and Mitral Valve Incompetence: Can be fatal. Discontinue and obtain cardiac evaluation if findings suggest these cardiac reactions.Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Clozapine is not approved for this condition.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, clozapine (the active ingredient contained in FazaClo) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking clozapine:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>confusion</li>
<li>constipation</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>fainting</li>
<li>fast, pounding, or irregular heartbeat or pulse</li>
<li>fever</li>
<li>nausea</li>
<li>shakiness in the legs, arms, hands, or feet</li>
<li>sleepiness or unusual drowsiness</li>
<li>sweating</li>
<li>trembling or shaking of the hands or feet</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Anxiety</li>
<li>black, tarry stools</li>
<li>chest pain</li>
<li>chills</li>
<li>convulsions</li>
<li>cough or hoarseness</li>
<li>decrease in the frequency of urination</li>
<li>decrease in urine volume</li>
<li>difficult or labored breathing</li>
<li>difficulty in passing urine (dribbling)</li>
<li>discouragement</li>
<li>dry mouth</li>
<li>feeling sad or empty</li>
<li>fever with or without chills</li>
<li>frequent strong or increased urge to urinate</li>
<li>general feeling of tiredness or weakness</li>
<li>headache</li>
<li>hyperventilation</li>
<li>irritability</li>
<li>lack of appetite</li>
<li>loss of bladder control</li>
<li>loss of interest or pleasure</li>
<li>lower back or side pain</li>
<li>muscle spasm or jerking of the arms or legs</li>
<li>painful or difficult urination</li>
<li>pounding in the ears</li>
<li>restlessness or need to keep moving</li>
<li>severe or continuing headache</li>
<li>shakiness and unsteady walk</li>
<li>slurred speech</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>sudden jerky movements of the body</li>
<li>sudden loss of consciousness</li>
<li>swollen glands</li>
<li>throat discomfort</li>
<li>tightness in the chest</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
<li>unsteadiness, trembling, or other problems with muscle control or coordination</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Absence of or decrease in movement</li>
<li>change in appetite</li>
<li>dark urine</li>
<li>decreased sexual ability</li>
<li>difficult or fast breathing or sudden shortness of breath</li>
<li>increased sweating</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>lip smacking or puckering</li>
<li>muscle stiffness (severe)</li>
<li>puffing of the cheeks</li>
<li>rapid or worm-like movements of the tongue</li>
<li>swelling or pain in the leg</li>
<li>uncontrolled chewing movements</li>
<li>uncontrolled movements of the arms and legs</li>
<li>unusual bleeding or bruising</li>
<li>unusually pale skin</li>
<li>weakness</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bloating</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>clay-colored stools</li>
<li>confusion as to time, place, or person</li>
<li>diarrhea</li>
<li>epileptic seizure that will not stop</li>
<li>feeling that others are watching you or controlling your behavior</li>
<li>feeling that others can hear your thoughts</li>
<li>feeling, seeing, or hearing things that are not there</li>
<li>holding false beliefs that cannot be changed by fact</li>
<li>inability to move the eyes</li>
<li>increased blinking or spasms of the eyelid</li>
<li>indigestion</li>
<li>itching or skin rash</li>
<li>joint pain</li>
<li>light-colored stools</li>
<li>muscle twitching</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>rhythmic movement of the muscles</li>
<li>severe mood or mental changes</li>
<li>sticking out of the tongue</li>
<li>swelling around the eyes</li>
<li>swelling of the body or feet and ankles</li>
<li>trouble with speaking</li>
<li>unpleasant breath odor</li>
<li>unusual behavior</li>
<li>unusual excitement, nervousness, or restlessness</li>
<li>unusual facial expressions</li>
<li>unusual weight gain</li>
<li>upper right abdominal or stomach pain</li>
<li>vomiting of blood</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of clozapine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching</li>
<li>feeling of constant movement of self or surroundings</li>
<li>heartburn</li>
<li>relaxed and calm sensation of spinning</li>
<li>sleepiness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blurred or loss of vision</li>
<li>change or problem with discharge of semen</li>
<li>disturbed color perception</li>
<li>double vision</li>
<li>halos around lights</li>
<li>inability to sit still</li>
<li>increase in body movements</li>
<li>muscle ache or pain</li>
<li>muscle weakness</li>
<li>night blindness</li>
<li>nightmares</li>
<li>overbright appearance of lights</li>
<li>pain in the back, neck, or legs</li>
<li>pain in the chest below the breastbone</li>
<li>severe muscle stiffness</li>
<li>sore tongue</li>
<li>stuffy nose</li>
<li>tunnel vision</li>
<li>unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>hives, sores, welting, or blisters</li>
<li>increased sensitivity of the skin to sunlight</li>
<li>painful or prolonged erection of the penis</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>reddening of the skin, especially around the ears</li>
<li>severe stomach pain</li>
<li>severe sunburn</li>
<li>swelling of the eyes, face, or inside of the nose</li>
<li>swelling of the salivary glands</li>
</ul><p>
<!-- end oral suspension, oral tablet, oral tablet disintegrating --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to clozapine: oral suspension, oral tablet, oral tablet disintegrating</i></p><h3>General</h3><p>The most commonly reported side effects included salivary hypersecretion, somnolence, and weight gain.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Salivary hypersecretion/hypersalivation (up to 48%), salivation (up to 31%), constipation (up to 25%), nausea (up to 17%), vomiting (up to 17%), dyspepsia (up to 14%)</p>
<p><b>Common</b> (1% to 10%): Abdominal discomfort/dyspepsia/heartburn, diarrhea, dry mouth</p>
<p><b>Rare</b> (0.01% to 0.1%): Acute pancreatitis, Dysphagia, ileus impaction, pancreatitis</p>
<p><b>Very rare</b> (less than 0.01%): Fecal impaction/intestinal obstruction/paralytic ileus, parotid gland enlargement</p>
<p><b>Frequency not reported</b>: Colitis, swallowing difficulty, tongue protrusion</p>
<p><b>Postmarketing reports</b>: Intestinal infarction/ischemia/fatal intestinal infarction/ischemia, megacolon/fatal megacolon, salivary gland swelling<sup>[Ref]</sup></p><h3>Nervous system</h3><p>The cumulative incidence of seizure at 1 year is approximately 5% based on pre-marketing testing. The risk is dose-related.</p>
<p></p>
<p>Extrapyramidal symptoms that occur appear to be milder and less frequent than other antipsychotic drugs. There have been no reports of tardive dyskinesia directly attributable to clozapine (the active ingredient contained in FazaClo)  however, the syndrome has been reported in a few patients who were treated with other antipsychotics prior to receiving clozapine. A causal relationship can neither be established nor excluded.</p>
<p></p>
<p>Cholinergic syndrome occurred after abrupt withdrawal.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Somnolence (up to 46%), drowsiness/sedation (up to 39%), dizziness (up to 27%), vertigo (up to 19%), headache (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Akathisia, akinesia, convulsions/myoclonic jerks/seizures, dysarthria, extrapyramidal symptoms, hypokinesia, syncope, tremor</p>
<p><b>Uncommon</b> (0.1% to 1%): Neuroleptic malignant syndrome</p>
<p><b>Very rare</b> (less than 0.01%): Tardive dyskinesia</p>
<p><b>Frequency not reported</b>: Dystonia</p>
<p><b>Postmarketing reports</b>: Abnormal EEG, cholinergic syndrome, clozapine-induced seizures, EEG changes, motor instability, myasthenic syndrome, myoclonus, paresthesia, pleurothotonus, possible cataplexy, post-discontinuation cholinergic rebound adverse reactions, sensory instability, status epilepticus<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Diabetes mellitus occurred in patients without a history of hyperglycemia or diabetes mellitus.</p>
<p></p>
<p>Pooled data from 8 studies in patients with schizophrenia found the mean change in fasting blood glucose in clozapine (the active ingredient contained in FazaClo) treated patients was +11 mg/dL; pooled data from 10 studies revealed clozapine treatment was associated a mean increase of 13 mg/dl in total cholesterol; pooled data from 11 studies showed a weight gain of 7% or greater relative to baseline body weight occurred in 35% of patients with a mean weight gain of 3.7 kg.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Increased weight/weight gain (up to 31%)</p>
<p><b>Common</b> (1% to 10%): Anorexia</p>
<p><b>Rare</b> (0.01% to 0.1%): Aggravated diabetes, diabetes mellitus, hyperosmolar coma, impaired glucose tolerance, ketoacidosis, severe hyperglycemia</p>
<p><b>Very rare</b> (less than 0.01%): Hypercholesterolemia, hypertriglyceridemia</p>
<p><b>Frequency not reported</b>: Pseudopheochromocytoma</p>
<p><b>Postmarketing reports</b>: Hypernatremia, hyperuricemia, obesity, weight loss<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Tachycardia (up to 25%), hypotension (up to 13%), hypertension (up to 12%)</p>
<p><b>Common</b> (1% to 10%): ECG changes, postural hypotension</p>
<p><b>Rare</b> (0.01% to 0.1%): Arrhythmias, circulatory collapse, myocarditis, pericardial effusion, pericarditis, thromboembolism, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia</p>
<p><b>Very rare</b> (less than 0.01%): Cardiac arrest, cardiomyopathy/clozapine-related cardiomyopathy, QT prolongation, skin reactions, Torsade de pointes</p>
<p><b>Frequency not reported</b>: Angina pectoris/chest pain, myocardial infarction/fatal myocardial infarction, pigmentation disorder, venous thromboembolism</p>
<p><b>Postmarketing reports</b>: Atrial fibrillation, deep vein thrombosis, mitral valve incompetence, palpitations<sup>[Ref]</sup></p><p>Isolated cases of cardiac arrhythmias, pericarditis/pericardial effusion, and myocarditis have been reported. Postmarketing, very rare events of ventricular tachycardia, cardiac arrest, and QT prolongation which may be associated with Torsades de pointes have been observed, although there is no conclusive causal relationship to use of this drug.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (up to 20%)</p>
<p><b>Common</b> (1% to 10%): Agitation, confusion, disturbed sleep/nightmares, restlessness</p>
<p><b>Uncommon</b> (0.1% to 1%): Dysphemia</p>
<p><b>Rare</b> (0.01% to 0.1%): Delirium, dream activity intensification</p>
<p><b>Very rare</b> (less than 0.01%): Obsessive compulsive disorder/symptoms</p>
<p><b>Frequency not reported</b>: Neonatal drug withdrawal syndrome<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever/hyperthermia (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Benign hyperthermia, fatigue, temperature regulation disturbance</p>
<p><b>Very rare</b> (less than 0.01%): Sudden unexplained death</p>
<p><b>Postmarketing reports</b>: Falls, polyserositis, sepsis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Decreased white blood cells, eosinophilia, leukocytosis, leukopenia, neutropenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Agranulocytosis</p>
<p><b>Rare</b> (0.01% to 0.1%): Anemia</p>
<p><b>Very rare</b> (less than 0.01%): Thrombocythemia, thrombocytopenia</p>
<p><b>Postmarketing reports</b>: Elevated hematocrit, elevated hemoglobin, granulocytopenia, increased erythrocyte sedimentation rate, mild leukopenia, moderate leukopenia, severe leukopenia, thrombocytosis<sup>[Ref]</sup></p><p>During pre-marketing testing, the cumulative incidence of agranulocytosis at one year was reported to be 1.3%. Based on Clozaril National Registry (US patients) data collected up to April 1995, a hematologic risk analysis found the incidence of agranulocytosis rises steeply during the first 2 months, peaks at approximately the third month, and decreases at 6 months of therapy; after 6 months, the incidence decreases further, however, it never reaches zero. Individuals with an initial episode of moderate leukopenia (WBC of at least 2000/mm3 and less than 3000/mm3) are at an increased risk of having a subsequent episode of agranulocytosis.</p>
<p></p>
<p>In the UK, agranulocytosis occurred within the first 18 weeks in approximately 70% of patients who developed the condition.</p>
<p></p>
<p>In clinical trials, eosinophil counts of greater than 700/mm3 occurred in approximately 1% of patients. Eosinophilia has been co-reported with some cases of myocarditis (approximately 14%) and pericarditis/pericardial effusion, although it is unknown whether eosinophilia is a reliable predictor of carditis.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary abnormalities, urinary incontinence, urinary retention</p>
<p><b>Very rare</b> (less than 0.01%): Dysmenorrhea, ejaculation change, impotence, priapism</p>
<p><b>Postmarketing reports</b>: Nocturnal enuresis, retrograde ejaculation<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, sweating/sweating disturbance</p>
<p><b>Frequency not reported</b>: Leukocytoclastic vasculitis</p>
<p><b>Postmarketing reports</b>: Erythema multiforme, photosensitivity, skin pigmentation disorder, Stevens-Johnson syndrome<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision, visual disturbances</p>
<p><b>Postmarketing reports</b>: Narrow angle glaucoma, periorbital edema<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated liver enzymes</p>
<p><b>Rare</b> (0.01% to 0.1%): Cholestasis, cholestatic jaundice, hepatitis</p>
<p><b>Very rare</b> (less than 0.01%): Fulminant hepatic necrosis</p>
<p><b>Postmarketing reports</b>: Cholestatic injury, hepatic cirrhosis, hepatic fibrosis, hepatic injury, hepatic necrosis, hepatic steatosis, hepatotoxicity, jaundice, liver failure, liver transplant, mixed injury<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Rigidity</p>
<p><b>Rare</b> (0.01% to 0.1%): Creatine phosphokinase elevation</p>
<p><b>Frequency not reported</b>: Muscle pain, muscle spasms, muscle weakness, neck muscle spasm, systemic lupus erythematosus</p>
<p><b>Postmarketing reports</b>: Rhabdomyolysis<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Aspiration of ingested food usually occurred in patients with dysphagia or in acute overdose.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Aspiration of ingested food, lower respiratory tract infection/fatal lower respiratory tract infection, pneumonia, pulmonary embolism, respiratory arrest, respiratory depression, respiratory depression/arrest with/without circulatory collapse</p>
<p><b>Very rare</b> (less than 0.01%): Allergic asthma</p>
<p><b>Frequency not reported</b>: Difficulty breathing, nasal congestion, throat tightness</p>
<p><b>Postmarketing reports</b>: Pleural effusion, sleep apnea/sleep apnea syndrome<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very rare</b> (less than 0.01%): Acute interstitial nephritis/interstitial nephritis</p>
<p><b>Postmarketing reports</b>: Renal failure<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Angioedema</p>
<p><b>Postmarketing reports</b>: hypersensitivity reactions<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Postmarketing reports</b>: Pseudopheochromocytoma<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. FazaClo (cloZAPine)." Jazz Pharmaceuticals, Palo Alto, CA. </p><p id="ref_2">2. "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_3">3. "Product Information. Versacloz (cloZAPine)." Jazz Pharmaceuticals, Palo Alto, CA. </p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_5">5. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about FazaClo (clozapine)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: atypical antipsychotics</li>
<li>FDA Alerts (8)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>FazaClo &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Clozaril, Versacloz</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Schizophrenia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to clozapine: oral suspension, oral tablet, oral tablet disintegrating</i></p><h3>General</h3><p>The most commonly reported side effects included salivary hypersecretion, somnolence, and weight gain.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Salivary hypersecretion/hypersalivation (up to 48%), salivation (up to 31%), constipation (up to 25%), nausea (up to 17%), vomiting (up to 17%), dyspepsia (up to 14%)</p><p><b>Common</b> (1% to 10%): Abdominal discomfort/dyspepsia/heartburn, diarrhea, dry mouth</p><p><b>Rare</b> (0.01% to 0.1%): Acute pancreatitis, Dysphagia, ileus impaction, pancreatitis</p><p><b>Very rare</b> (less than 0.01%): Fecal impaction/intestinal obstruction/paralytic ileus, parotid gland enlargement</p><p><b>Frequency not reported</b>: Colitis, swallowing difficulty, tongue protrusion</p><p><b>Postmarketing reports</b>: Intestinal infarction/ischemia/fatal intestinal infarction/ischemia, megacolon/fatal megacolon, salivary gland swelling<sup>[Ref]</sup></p><h3>Nervous system</h3><p>The cumulative incidence of seizure at 1 year is approximately 5% based on pre-marketing testing. The risk is dose-related.</p><p></p><p>Extrapyramidal symptoms that occur appear to be milder and less frequent than other antipsychotic drugs. There have been no reports of tardive dyskinesia directly attributable to clozapine (the active ingredient contained in FazaClo)  however, the syndrome has been reported in a few patients who were treated with other antipsychotics prior to receiving clozapine. A causal relationship can neither be established nor excluded.</p><p></p><p>Cholinergic syndrome occurred after abrupt withdrawal.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Somnolence (up to 46%), drowsiness/sedation (up to 39%), dizziness (up to 27%), vertigo (up to 19%), headache (up to 10%)</p><p><b>Common</b> (1% to 10%): Akathisia, akinesia, convulsions/myoclonic jerks/seizures, dysarthria, extrapyramidal symptoms, hypokinesia, syncope, tremor</p><p><b>Uncommon</b> (0.1% to 1%): Neuroleptic malignant syndrome</p><p><b>Very rare</b> (less than 0.01%): Tardive dyskinesia</p><p><b>Frequency not reported</b>: Dystonia</p><p><b>Postmarketing reports</b>: Abnormal EEG, cholinergic syndrome, clozapine-induced seizures, EEG changes, motor instability, myasthenic syndrome, myoclonus, paresthesia, pleurothotonus, possible cataplexy, post-discontinuation cholinergic rebound adverse reactions, sensory instability, status epilepticus<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Diabetes mellitus occurred in patients without a history of hyperglycemia or diabetes mellitus.</p><p></p><p>Pooled data from 8 studies in patients with schizophrenia found the mean change in fasting blood glucose in clozapine (the active ingredient contained in FazaClo) treated patients was +11 mg/dL; pooled data from 10 studies revealed clozapine treatment was associated a mean increase of 13 mg/dl in total cholesterol; pooled data from 11 studies showed a weight gain of 7% or greater relative to baseline body weight occurred in 35% of patients with a mean weight gain of 3.7 kg.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Increased weight/weight gain (up to 31%)</p><p><b>Common</b> (1% to 10%): Anorexia</p><p><b>Rare</b> (0.01% to 0.1%): Aggravated diabetes, diabetes mellitus, hyperosmolar coma, impaired glucose tolerance, ketoacidosis, severe hyperglycemia</p><p><b>Very rare</b> (less than 0.01%): Hypercholesterolemia, hypertriglyceridemia</p><p><b>Frequency not reported</b>: Pseudopheochromocytoma</p><p><b>Postmarketing reports</b>: Hypernatremia, hyperuricemia, obesity, weight loss<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Tachycardia (up to 25%), hypotension (up to 13%), hypertension (up to 12%)</p><p><b>Common</b> (1% to 10%): ECG changes, postural hypotension</p><p><b>Rare</b> (0.01% to 0.1%): Arrhythmias, circulatory collapse, myocarditis, pericardial effusion, pericarditis, thromboembolism, ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia</p><p><b>Very rare</b> (less than 0.01%): Cardiac arrest, cardiomyopathy/clozapine-related cardiomyopathy, QT prolongation, skin reactions, Torsade de pointes</p><p><b>Frequency not reported</b>: Angina pectoris/chest pain, myocardial infarction/fatal myocardial infarction, pigmentation disorder, venous thromboembolism</p><p><b>Postmarketing reports</b>: Atrial fibrillation, deep vein thrombosis, mitral valve incompetence, palpitations<sup>[Ref]</sup></p><p>Isolated cases of cardiac arrhythmias, pericarditis/pericardial effusion, and myocarditis have been reported. Postmarketing, very rare events of ventricular tachycardia, cardiac arrest, and QT prolongation which may be associated with Torsades de pointes have been observed, although there is no conclusive causal relationship to use of this drug.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (up to 20%)</p><p><b>Common</b> (1% to 10%): Agitation, confusion, disturbed sleep/nightmares, restlessness</p><p><b>Uncommon</b> (0.1% to 1%): Dysphemia</p><p><b>Rare</b> (0.01% to 0.1%): Delirium, dream activity intensification</p><p><b>Very rare</b> (less than 0.01%): Obsessive compulsive disorder/symptoms</p><p><b>Frequency not reported</b>: Neonatal drug withdrawal syndrome<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fever/hyperthermia (up to 13%)</p><p><b>Common</b> (1% to 10%): Benign hyperthermia, fatigue, temperature regulation disturbance</p><p><b>Very rare</b> (less than 0.01%): Sudden unexplained death</p><p><b>Postmarketing reports</b>: Falls, polyserositis, sepsis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Decreased white blood cells, eosinophilia, leukocytosis, leukopenia, neutropenia</p><p><b>Uncommon</b> (0.1% to 1%): Agranulocytosis</p><p><b>Rare</b> (0.01% to 0.1%): Anemia</p><p><b>Very rare</b> (less than 0.01%): Thrombocythemia, thrombocytopenia</p><p><b>Postmarketing reports</b>: Elevated hematocrit, elevated hemoglobin, granulocytopenia, increased erythrocyte sedimentation rate, mild leukopenia, moderate leukopenia, severe leukopenia, thrombocytosis<sup>[Ref]</sup></p><p>During pre-marketing testing, the cumulative incidence of agranulocytosis at one year was reported to be 1.3%. Based on Clozaril National Registry (US patients) data collected up to April 1995, a hematologic risk analysis found the incidence of agranulocytosis rises steeply during the first 2 months, peaks at approximately the third month, and decreases at 6 months of therapy; after 6 months, the incidence decreases further, however, it never reaches zero. Individuals with an initial episode of moderate leukopenia (WBC of at least 2000/mm3 and less than 3000/mm3) are at an increased risk of having a subsequent episode of agranulocytosis.</p><p></p><p>In the UK, agranulocytosis occurred within the first 18 weeks in approximately 70% of patients who developed the condition.</p><p></p><p>In clinical trials, eosinophil counts of greater than 700/mm3 occurred in approximately 1% of patients. Eosinophilia has been co-reported with some cases of myocarditis (approximately 14%) and pericarditis/pericardial effusion, although it is unknown whether eosinophilia is a reliable predictor of carditis.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary abnormalities, urinary incontinence, urinary retention</p><p><b>Very rare</b> (less than 0.01%): Dysmenorrhea, ejaculation change, impotence, priapism</p><p><b>Postmarketing reports</b>: Nocturnal enuresis, retrograde ejaculation<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, sweating/sweating disturbance</p><p><b>Frequency not reported</b>: Leukocytoclastic vasculitis</p><p><b>Postmarketing reports</b>: Erythema multiforme, photosensitivity, skin pigmentation disorder, Stevens-Johnson syndrome<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision, visual disturbances</p><p><b>Postmarketing reports</b>: Narrow angle glaucoma, periorbital edema<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Elevated liver enzymes</p><p><b>Rare</b> (0.01% to 0.1%): Cholestasis, cholestatic jaundice, hepatitis</p><p><b>Very rare</b> (less than 0.01%): Fulminant hepatic necrosis</p><p><b>Postmarketing reports</b>: Cholestatic injury, hepatic cirrhosis, hepatic fibrosis, hepatic injury, hepatic necrosis, hepatic steatosis, hepatotoxicity, jaundice, liver failure, liver transplant, mixed injury<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Rigidity</p><p><b>Rare</b> (0.01% to 0.1%): Creatine phosphokinase elevation</p><p><b>Frequency not reported</b>: Muscle pain, muscle spasms, muscle weakness, neck muscle spasm, systemic lupus erythematosus</p><p><b>Postmarketing reports</b>: Rhabdomyolysis<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Aspiration of ingested food usually occurred in patients with dysphagia or in acute overdose.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Aspiration of ingested food, lower respiratory tract infection/fatal lower respiratory tract infection, pneumonia, pulmonary embolism, respiratory arrest, respiratory depression, respiratory depression/arrest with/without circulatory collapse</p><p><b>Very rare</b> (less than 0.01%): Allergic asthma</p><p><b>Frequency not reported</b>: Difficulty breathing, nasal congestion, throat tightness</p><p><b>Postmarketing reports</b>: Pleural effusion, sleep apnea/sleep apnea syndrome<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very rare</b> (less than 0.01%): Acute interstitial nephritis/interstitial nephritis</p><p><b>Postmarketing reports</b>: Renal failure<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Angioedema</p><p><b>Postmarketing reports</b>: hypersensitivity reactions<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Postmarketing reports</b>: Pseudopheochromocytoma<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. FazaClo (cloZAPine)." Jazz Pharmaceuticals, Palo Alto, CA. </p><p id="ref_2">2. "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_3">3. "Product Information. Versacloz (cloZAPine)." Jazz Pharmaceuticals, Palo Alto, CA. </p><p id="ref_4">4. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_5">5. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about FazaClo (clozapine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: atypical antipsychotics</li>
<li>FDA Alerts (8)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>FazaClo &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Schizophrenia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>